Huawei P Smart 2021 fast charging arrives November, autonomy and price content as main claims: Huawei has introduced a new device that will become part of its family P Smart with quadruple camera, long battery life and fast charge of 22.5 W as main claims.
The new Huawei P Smart 2021 comes with a Full HD screen of 6.67 inches and resolution 2400x1080 and the truth is that it does at a very attractive price: 229 euros for a single version of 4G RAM and 128 GB of internal memory.
Going into detail, the most relevant data of the new device of the Chinese company is its 5,000 mAh battery that promises to last as little as two days at full performance, as well as a fast charge of 22.5 W capable of achieving 0 to 100 in an hour and a half. The interesting thing, Huawei points out, is that with just 10 minutes of charge you can get up to 2 hours of viewing audiovisual content.
Huawei P Smart 2021 fast charging arrives November
As for the photographic section, the P Smart 2021 comes with a quadruple rear camera with a main lens of 48 megapixels that promises clear and well-defined results, a wide angle of 8 megapixels, portrait mode of 2 megapixels, as well as a macro mode of 2 megapixels. The selfie camera, for its part, is left with a lens of 8 megapixels.
It should also be noted that inside it saves a Kirin 710a processor, manufactured by Huawei, which works as the engine of this device and that will let you enjoy the device without any problems and install anything you get off the AppGallery, since as it is already a usual on Huawei phones by the veto of Trump, comes without Google services.
An interesting point is that from the Chinese company have wanted to enhance everything related to Entertainment and include a package of HMS service offerings that further improve the user experience: three months of Huawei Music and Huawei Video + Free, and 15GB in Huawei Cloud free for 1 year.
The device will go on sale in November on the Huawei website, as well as in selected retailers in three colors: Crush Green, Blush Gold and Midnight Black.
Huawei P Smart 2021 fast charging arrives November
Who is behind the top investment funds interested in startups looking to increase your life expectancy
Marc Ramis, CEO of Senolytic Therapeutics, a startup that investigates the possibility of reducing diseases associated with aging through the elimination of senescent cells and which form part of the portfolio of the american Life Biosciences, says that the science of longevity found investors with ease outside of Spain.
The global anti-aging market is estimated to exceed $ 271 billion by 2024. In fact, in 2018 investors invested more than $ 850 million in aging and longevity startups, according to CB Insights.
Ramis explains that it is common for investments in this sector to come from the hands of billionaires interested in living forever, but not necessarily specialized in the sector.
"The main challenge then is to connect with the entire pharmaceutical and more specialized ecosystem," acknowledges Ramis, who has also founded another company based on the same science as Senolytic Therapeutics with the support of a fund in Switzerland.
The same Jeff Bezos, CEO of Amazon and the richest man in the world, has made several investments in longevity startups. Another tycoon known for his financial support to companies seeking the strength of eternal youth is Peter Thiel, co-founder of PayPal.
In Europe and the United States, there are already investment funds focused exclusively on longevity and anti-aging startups. While some are led by well-known figures in biotechnology and Science, others face large billionaires looking for ways to live forever.
Rejuveron (Switzerland) CEO: Matthias Steger.
The company itself defines itself as a company that " invests in drugs and technologies that have the potential to significantly extend the lives of human beings." Among its portfolio is Rejuversen, the startup of Ramis focused on developing a monoclonal antibody that can eliminate senescence caused by cancer treatments and increases the possibility of relapse.
Steger is also the CEO of endogenous Therapeutics, a company focused on "discovering and developing first-class regenerative medicines to repair and regenerate tissues and organs" with the goal of " effectively addressing the unmet medical needs associated with aging and genetic diseases."
Apollo Health Ventures (Germany) Founders: Nils Regge and Alexandra Sharon Bause.
Apollo is focused on investing in early-stage startups with the potential to prevent or reverse age-associated diseases.
Alexandra Bause previously worked with the Boston Consulting Group, where she specialized in biopharmaceutical market strategy and assessment, market assessment and asset diligence.
His doctoral studies at Harvard Medical School focused on the research of molecular mechanisms that contribute to cellular aging.
For his part, Nils Regge is a serial entrepreneur and founded the truventuro investment fund in 2010, and has participated in more than 30 rounds of financing as an investor or co-founder among the companies he co-founded. Among them, 3 have achieved a valuation of more than $ 100 million.
Juvenescence (United Kingdom) Founders: Jim Mellon.
Since 2017, Juvenescence has raised $ 150 million to build a portfolio of startups focused on treating aging and associated diseases.
Jim Mellon is an economy guru, philanthropist and billionaire who makes international investments in various industries.
He worked in Asia and the United States for two fund management companies, GT and Thornton, before setting up his own business in 1991.
Its trading operations include a publicly traded fund management company called Charlemagne Capital, and an Asian Mining Group, Regent Pacific. He is also co-chair of West African Minerals Corporation and Regent Pacific Group.
He is also on the board of several listed companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited and Speymill plc.
He has written several books on the future of venture capital and, in particular, on how to leverage the biotechnology sector.
The founder has recently assured that he wants Juvenescence to go public in between six months and a year.
LifeBioscience, (United States) CEO: David Sinclair.
Life Biosciences has a portfolio of six startups that operate semi-independently and work on different projects, but all related to the science of aging, including the Spanish Senolytic Therapeutics.
As Juvenescence, Life Biosciences works as a mixed model, partly an investor and partly a company that brings startups together with the same goal.
Sinclair is an Australian biologist, Professor of genetics and co-director of the Paul F. Glenn Center for Aging Biology at Harvard Medical School.
He was chosen as one of the most influential people in the world by Time magazine and in 2018 was also included in the list of the 50 Most Influential People in health.